UME

SeaWorld Orlando Returns Mother-Daughter Manatee Pair to Florida Waters After More than a Year of Rehabilitation and 17,000+ Hours of Specialized Care

Retrieved on: 
Thursday, January 18, 2024

ORLANDO, Fla., Jan. 18, 2024 /PRNewswire/ -- Today, SeaWorld Orlando successfully returned Reckless and Churro, a mother and calf manatee duo, to Broward County in Florida after more than a year of incredible rehabilitation at its Rescue Center. The rehabilitation work included 12 lifesaving procedures and more than 17,000 hours of specialized care.

Key Points: 
  • The rehabilitation work included 12 lifesaving procedures and more than 17,000 hours of specialized care.
  • Reckless and Churro were rescued in Florida in May 2022 by the Florida Fish and Wildlife Conservation Commission (FWC) and SeaWorld after Reckless suffered a catastrophic boat strike.
  • Given Reckless' extensive injuries, the mother-daughter pair required over 17,000 hours of specialized care to keep them both healthy throughout the intensive rehabilitation process.
  • SeaWorld Orlando has the largest manatee rescue operation in the U.S., and one of only three critical care centers.

Luscii Supports Essen University Hospital on the further path to a "Smart Hospital"

Retrieved on: 
Monday, January 15, 2024

UTRECHT, Netherlands, Jan. 15, 2024 /PRNewswire/ -- Essen University Hospital (UME) will rely on the leading digital health platform Luscii for the remote monitoring of patients with respiratory diseases.

Key Points: 
  • UTRECHT, Netherlands, Jan. 15, 2024 /PRNewswire/ -- Essen University Hospital (UME) will rely on the leading digital health platform Luscii for the remote monitoring of patients with respiratory diseases.
  • Oliver Witzke, is part of the "Smart Hospital" strategy of Essen University Hospital.
  • In the pilot project, participating patients receive the Luscii app to input data within a structured treatment path for pneumonia.
  • "Essen University Hospital sees digitization as a unique opportunity to shape the hospital of the future—with a clear focus on people as patients and employees.

Luscii Supports Essen University Hospital on the further path to a "Smart Hospital"

Retrieved on: 
Monday, January 15, 2024

UTRECHT, Netherlands, Jan. 15, 2024 /PRNewswire/ -- Essen University Hospital (UME) will rely on the leading digital health platform Luscii for the remote monitoring of patients with respiratory diseases.

Key Points: 
  • UTRECHT, Netherlands, Jan. 15, 2024 /PRNewswire/ -- Essen University Hospital (UME) will rely on the leading digital health platform Luscii for the remote monitoring of patients with respiratory diseases.
  • Oliver Witzke, is part of the "Smart Hospital" strategy of Essen University Hospital.
  • In the pilot project, participating patients receive the Luscii app to input data within a structured treatment path for pneumonia.
  • "Essen University Hospital sees digitization as a unique opportunity to shape the hospital of the future—with a clear focus on people as patients and employees.

Oculis Reports Q3 2023 Financial Results and Provides Company Update

Retrieved on: 
Wednesday, November 15, 2023

ZUG, Switzerland and BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced third quarter financial results for the period ended September 30, 2023, and an overview of the Company’s progress.

Key Points: 
  • ZUG, Switzerland and BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced third quarter financial results for the period ended September 30, 2023, and an overview of the Company’s progress.
  • Oculis anticipates first patient enrollment toward the end of 2023 and beginning of 2024 in all three pivotal trials.
  • Oculis is on track to deliver the first patient first visit before the end of 2023 with clinical data readout expected in mid-2024.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023

ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Other Income: Other income for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.
  • Other Expense: Non-cash interest expense for the third quarter of 2023 was $2.6 million, compared to $1.3 million in the third quarter of 2022.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Following Extreme Drought and Heat, SeaWorld Conservation Fund Makes Emergency Grant to Help Save Endangered Amazon River Dolphins in Brazil

Retrieved on: 
Thursday, November 30, 2023

ORLANDO, Fla., Nov. 30, 2023 /PRNewswire/ -- Following extreme drought and heat in the Brazilian Amazon rainforest, the SeaWorld Conservation Fund made an emergency grant to the Mamirauá Institute for Sustainable Development (IDSM) to support the rescue of Amazon river dolphins and mitigate the impact of the environmental emergency in and around Lake Tefé, located in the Brazilian Amazon rainforest. Amazon river dolphins, many of a striking pink color, are a unique freshwater species found only in the rivers of South America and are one of a handful of freshwater dolphin species left in the world. The IDSM is using this grant to further its efforts in recovering dolphin carcasses and gathering biological samples for analyses, with the goal of determining the cause of death. Additionally, IDSM is implementing a comprehensive rescue plan to rescue, treat and translocate healthy dolphins to a more suitable natural habitat.

Key Points: 
  • The SeaWorld Conservation Fund provides grants around the world to grassroots conservation projects that make a difference in species research, habitat protection, conservation education and animal rescue and rehabilitation.
  • To date, there have been 154 Amazon river dolphin casualties reported, including both the pink river dolphins and tucuxi dolphins.
  • The Tefé Dolphins Emergency Operation, launched by the Chico Mendes Institute for Biodiversity Conservation (ICMBio) with technical support from IDSM, monitors the Amazon river dolphins.
  • Since the beginning of the crisis, there have been 154 deceased Amazon river dolphins, with 131 pink river dolphins and 23 tucuxis.

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

Retrieved on: 
Thursday, November 2, 2023

After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support.

Key Points: 
  • After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support.
  • To develop the AI models, GE HealthCare and VUMC retrospectively analyzed and correlated the immunotherapy treatment response of thousands of VUMC cancer patients, with their deidentified demographic, genomic, tumor, cellular, proteomic, and imaging data.
  • “These results are a promising development in the journey towards precision care, selecting treatment pathways based on the individual patient’s likely response.
  • The AI models are an integral part of GE HealthCare’s immuno-oncology development portfolio which includes the development of novel PET tracers.

NRMP®'s Transition to Residency Conference to be held October 5 - 7, 2023 in Boston

Retrieved on: 
Monday, September 11, 2023

WASHINGTON, Sept. 11, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) is pleased to announce its national in-person stakeholder conference, Transition to Residency: Conversations Across the Medical Education Continuum, will take place October 5 – 7, 2023, in Boston, MA. The conference provides a unique opportunity for members of the medical education community, including medical schools, residency programs, resident physicians, and medical students, to come together, network, and collaborate on ways to improve the transition to residency and support young physicians.

Key Points: 
  • The conference provides a unique opportunity for members of the medical education community, including medical schools, residency programs, resident physicians, and medical students, to come together, network, and collaborate on ways to improve the transition to residency and support young physicians.
  • "We're looking forward to welcoming residency program and medical school faculty along with learners to Boston this year," said NRMP President and CEO Donna L. Lamb, DHSc, MBA, BSN.
  • "This conference affords the NRMP the opportunity to engage with attendees and consider consequential changes to the transition to residency, what those could mean for learners, and how such changes could improve or impair the transition.
  • This year's conference theme, The Next 70 Years: Our Imperative to Build a Better Transition to Residency, is designed to get attendees thinking about the future of the Match.

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, August 29, 2023

Riad Sherif MD, Chief Executive Officer of Oculis: “This has been a very exciting period for Oculis.

Key Points: 
  • Riad Sherif MD, Chief Executive Officer of Oculis: “This has been a very exciting period for Oculis.
  • Reported positive topline results in August 2023 from Phase 3 OPTIMIZE trial of OCS-01 in treating inflammation and pain following ocular surgery.
  • Both trials concluded in 2023 and achieved positive topline results as announced in May and August of 2023.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema

Retrieved on: 
Wednesday, August 2, 2023

CME may occur as a complication of ocular conditions, including uveitis and ocular surgery, and is a leading cause of vision loss worldwide.

Key Points: 
  • CME may occur as a complication of ocular conditions, including uveitis and ocular surgery, and is a leading cause of vision loss worldwide.
  • It is one of the most significant causes of postoperative vision loss after cataract surgery1.
  • CME is being explored with OCS-01 eye drops, in addition to diabetic macular edema (DME) and inflammation and pain post ocular surgery, both indications currently in Phase 3 clinical development.
  • Seven-year outcomes of uveitic macular edema: the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study results, Ophthalmology, May 2021 128 (5): 719-728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943640/